Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE GE Information Supply Fee to Be Introduced: Revision -2-
March 4, 2002
-
ARCHIVE New 3-Drug Therapy Using Omeprazole to Be Approved for Hp Eradication
March 4, 2002
-
ARCHIVE Advaferon and Rebetol + Intron A Effective for Refractory Hepatitis C
March 4, 2002
-
ARCHIVE Number of Drugs Approved in 2001 Totals About 2,400
March 4, 2002
-
ARCHIVE Japan, Singapore to Cooperate in the Field of Biomaterials
March 4, 2002
-
ARCHIVE Precautions for 4 Drugs Including Acarbose Revised
March 4, 2002
-
ARCHIVE Novo Nordisk Offers Grant for Research on Low Stature
March 4, 2002
-
ARCHIVE Administration Restrictions on IFN Lifted
March 4, 2002
-
ARCHIVE Abolition of Long-term Admission Fees from Insurance Coverage Hits Hospitals:Dr Itouji of JMA
March 4, 2002
-
ARCHIVE Korosho Calls on Medical Professionals to Cooperate in Immediate PMS
March 4, 2002
-
ARCHIVE Bungyo Rate Increases to 44.9% in October 2001
March 4, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
March 4, 2002
-
ARCHIVE AJHA Holds 1st Seminar on TQM
March 4, 2002
-
ARCHIVE BULLETIN
March 4, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 4, 2002
-
ARCHIVE Spin-off of Manufacturing Plants to Increase: PAL Revision
March 4, 2002
-
ARCHIVE 12,558 Drugstores Operated by 590 Companies: JACDS Survey
March 4, 2002
-
ARCHIVE Study Group Proposes Proper Drug Distribution System
March 4, 2002
-
ARCHIVE Taisho Appeals against Daikoku
March 4, 2002
-
ARCHIVE Manufacturers' FTC Issues Guide Regarding Entertainment
March 4, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…